These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19542396)

  • 41. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
    Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
    Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Large sample of nephrogenic systemic fibrosis cases from a single institution.
    Lee CU; Wood CM; Hesley GK; Leung N; Bridges MD; Lund JT; Lee PU; Pittelkow MR
    Arch Dermatol; 2009 Oct; 145(10):1095-102. PubMed ID: 19841395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents.
    Langer RD; Lorke DE; Neidl van Gorkom KF; Petroianu G; Azimullah S; Nurulain SM; Singh S; Fuchsjäger M
    Eur J Radiol; 2012 Oct; 81(10):2562-7. PubMed ID: 22304979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis.
    Kelly BC; Markle LS; Vickers JL; Petitt MS; Raimer SS; McNeese C
    J Am Acad Dermatol; 2010 Sep; 63(3):483-9. PubMed ID: 20708474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nephrogenic systemic fibrosis: some considerations on the debate regarding its cause.
    Provenzale JM
    AJR Am J Roentgenol; 2008 Dec; 191(6):1867-9. PubMed ID: 19020262
    [No Abstract]   [Full Text] [Related]  

  • 46. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report.
    Wiedemeyer K; Kutzner H; Abraham JL; Thakral C; Carlson JA; Tran TA; Hausser I; Hartschuh W
    Am J Dermatopathol; 2009 Oct; 31(7):674-81. PubMed ID: 19633532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 49. Which laboratory parameters are characteristic for nephrogenic systemic fibrosis?
    Boehm I
    Nephrol Dial Transplant; 2009 Jul; 24(7):2293; author reply 2293-4. PubMed ID: 19357110
    [No Abstract]   [Full Text] [Related]  

  • 50. Neuromuscular involvement in nephrogenic systemic fibrosis.
    Keyrouz S; Rudnicki SA
    J Clin Neuromuscul Dis; 2007 Dec; 9(2):297-302. PubMed ID: 18090682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nephrogenic systemic fibrosis an unsolved riddle.
    Graziani G; Montanelli A; Brambilla S; Balzarini L
    J Nephrol; 2009; 22(2):203-7. PubMed ID: 19384837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
    J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital.
    Zou Z; Ma L; Li H
    J Magn Reson Imaging; 2009 Dec; 30(6):1309-12. PubMed ID: 19937931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.
    Kendrick-Jones JC; Voss DM; De Zoysa JR
    Nephrology (Carlton); 2011 Feb; 16(2):243-8. PubMed ID: 21272139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nephrogenic systemic fibrosis: late skin manifestations.
    Bangsgaard N; Marckmann P; Rossen K; Skov L
    Arch Dermatol; 2009 Feb; 145(2):183-7. PubMed ID: 19221265
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nephrogenic systemic fibrosis: a review of the new conundrum.
    Goenka AH; Das CJ; Sharma R
    Natl Med J India; 2009; 22(6):302-6. PubMed ID: 20384019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
    Gupta A; Shamseddin MK; Khaira A
    Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.
    Schieren G; Wirtz N; Altmeyer P; Rump LC; Weiner SM; Kreuter A
    J Am Acad Dermatol; 2009 Nov; 61(5):868-74. PubMed ID: 19836645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Nephrogenic systemic fibrosis].
    Adar T; Rubinger D; Lalazar G; Levi L; Mizrahi M; Bogot RN
    Harefuah; 2008 Oct; 147(10):801-3, 837. PubMed ID: 19039911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.
    Kadiyala D; Roer DA; Perazella MA
    Am J Kidney Dis; 2009 Jan; 53(1):133-7. PubMed ID: 19022548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.